Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 6Head & Neck 2Gynecologic 2Gastrointestinal 2Breast 2Thoracic 1

Conditions

Ovarian Neoplasms 23Peritoneal Neoplasms 18Colorectal Neoplasms 10Stomach Neoplasms 9Fallopian Tube Neoplasms 8Endometrial Neoplasms 8Colonic Neoplasms 7Neoplasm Metastasis 6Carcinoma, Ovarian Epithelial 6Rectal Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Pancreatic Neoplasms 4Carcinoma, Renal Cell 4Appendiceal Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Neoplasms 3Esophageal Neoplasms 3Carcinoma, Hepatocellular 3Uterine Neoplasms 2Urinary Bladder Neoplasms 2Pseudomyxoma Peritonei 2Prostatic Neoplasms 2Neuroblastoma 2Melanoma 2Lung Neoplasms 2Gallbladder Neoplasms 2Cholangiocarcinoma 2Breast Neoplasms 2

Interventions

pembrolizumab 17Carboplatin 10Paclitaxel 7Trastuzumab 5Nivolumab 5Gemcitabine 5Early Intervention, Educational 5Cyclophosphamide 5Cisplatin 5fludarabine 4cemiplimab 4Psychiatric Rehabilitation 4Fluorouracil 4Docetaxel 4Counseling 4Albumin-Bound Paclitaxel 4tisotumab vedotin 3belinostat 3Radiotherapy 3Polymerase Chain Reaction 3Methods 3Magnetic Resonance Spectroscopy 3Gene Expression Profiling 3Fluorodeoxyglucose F18 3Biopsy 3zimberelimab 2ulixertinib 2pertuzumab 2palbociclib 2osimertinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × Oxaliplatin × Gynecologic × Clear all
NCT05891171 2026-03-31

ARC-25

Arcus Biosciences, Inc.

Phase 1 Active not recruiting
40 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

Merck Sharp & Dohme LLC

Phase 2 Completed
613 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡